Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00240929 · ClinicalTrials.gov registry record · Phase 2
A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)
A Phase 2 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
NCT00240929 is a Phase 2 study that has completed, run by MedImmune. The registered enrollment target is 150 participants.
The verdict
NCT00240929, a Phase 2 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
Study Summary
A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B.
Interventions
- DRUG MEDI-493
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2002-09 |
| Est. Completion | 2003-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00240929
The ClinicalTrials.gov registry entry for NCT00240929 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MEDI-493 is the first listed.
NCT00240929 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00240929 about?
NCT00240929 is a clinical study titled "A Phase II Randomized, Double-Blind, Two-Period Cross-Over Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a Liquid Formulation of Palizvizumab (MEDI-493, Synagis)". A total of 150 children who meet the entry criteria will be randomized 1:1 to receive one of the following treatment sequence A or B.
What is the current status of trial NCT00240929?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2002-09. Estimated completion is 2003-04.
What interventions are being tested in trial NCT00240929?
The interventions under investigation include: MEDI-493 (DRUG).
Who is sponsoring clinical trial NCT00240929?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.